Compass Therapeutics (CMPX) Enterprise Value (2023 - 2025)
Historic Enterprise Value for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$220.5 million.
- Compass Therapeutics' Enterprise Value fell 6214.09% to -$220.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$220.5 million, marking a year-over-year decrease of 6214.09%. This contributed to the annual value of -$127.3 million for FY2024, which is 1650.98% up from last year.
- Compass Therapeutics' Enterprise Value amounted to -$220.5 million in Q3 2025, which was down 6214.09% from -$101.5 million recorded in Q2 2025.
- Compass Therapeutics' 5-year Enterprise Value high stood at -$101.5 million for Q2 2025, and its period low was -$220.5 million during Q3 2025.
- Its 3-year average for Enterprise Value is -$152.8 million, with a median of -$152.5 million in 2023.
- Examining YoY changes over the last 5 years, Compass Therapeutics' Enterprise Value showed a top increase of 3570.35% in 2025 and a maximum decrease of 6214.09% in 2025.
- Quarter analysis of 3 years shows Compass Therapeutics' Enterprise Value stood at -$152.5 million in 2023, then rose by 16.51% to -$127.3 million in 2024, then crashed by 73.2% to -$220.5 million in 2025.
- Its Enterprise Value stands at -$220.5 million for Q3 2025, versus -$101.5 million for Q2 2025 and -$113.2 million for Q1 2025.